Company news
Aptorum Group Limited (NASDAQ:APM) news
Aptorum Group Limited news releases on 6ix. Latest, Sep 8, 2026: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releases & updates
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
September 8, 2026
Aptorum Group Provides Update on DiamiR Biosciences Merger
July 16, 2026
Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference
July 8, 2026
Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
June 21, 2026
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
June 10, 2026
Andean Precious Metals Appoints Victor Flores as Senior Vice President, Exploration, Operations and Growth
April 14, 2026
Andean Precious Metals Reports Strong First Quarter 2026 Production Results
April 8, 2026
Andean Advises of Senior Management Change
March 27, 2026
Andean Precious Metals Reports Fourth Quarter and Year-End 2025 Financial Results
March 25, 2026
Andean Precious Metals Announces Inclusion in VanEck Junior Gold Miners ETF (GDXJ)
March 18, 2026
Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania
March 10, 2026
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
February 2, 2026
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
November 19, 2025
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
October 10, 2025
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
October 9, 2025
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 5, 2025
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR’s APOE Genotyping Test
August 21, 2025
Aptorum Group Limited Regains Compliance with NASDAQ’s Minimum Bid Price Requirement
August 4, 2025
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
July 16, 2025
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 16, 2025
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
January 1, 2025
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
December 19, 2024
Aptorum : Current Report by Foreign Issuer (Form 6-K)
December 11, 2024
Aptorum : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Form 6 K
November 8, 2024
Aptorum : Merger Agreement - Form 6-K
May 31, 2024
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
April 29, 2024
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
March 5, 2024
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
December 21, 2023
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
December 20, 2023
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
November 15, 2023
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
August 9, 2023
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
June 21, 2023
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
June 8, 2023
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
March 26, 2023
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
March 2, 2023
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
March 2, 2023
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
March 1, 2023
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
February 5, 2023
Aptorum Group Announces 1-for-10 Reverse Stock Split
January 19, 2023
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
January 3, 2023
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
December 21, 2022
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
December 15, 2022
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
December 8, 2022
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
November 7, 2022
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
September 29, 2022
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
September 14, 2022
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 1, 2022
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
April 28, 2022
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 19, 2022
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
January 9, 2022